(Q24322825)

GOA release 2020-03-11

response to drug

1 reference

Annick Mühlethaler-Mottet

GOA release 2020-03-11

1 reference

object named as

A Mühlethaler-Mottet

9

0 references

author name string

M Flahaut

1

0 references

R Meier

2

0 references

A Coulon

3

0 references

K A Nardou

4

0 references

F K Niggli

5

0 references

D Martinet

6

0 references

J S Beckmann

7

0 references

J-M Joseph

8

0 references

N Gross

Wnt/beta-catenin signaling in development and disease

10

0 references

language of work or name

English

0 references

publication date

11 June 2009

0 references

published in

Oncogene

0 references

volume

28

0 references

issue

23

0 references

page(s)

2245-56

0 references

cites work

1 reference

Functional interaction between beta-catenin and FOXO in oxidative stress signaling

21 April 2017

1 reference

Multidrug resistance in cancer: role of ATP-dependent transporters

21 April 2017

1 reference

Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors

21 April 2017

1 reference

RACE: Remote Analysis Computation for gene Expression data

21 April 2017

1 reference

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

21 April 2017

1 reference

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Role of the MRP1/ABCC1 multidrug transporter protein in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

The APC gene product in normal and tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Frizzled-7 as a potential therapeutic target in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Phenotypic and genotypic diversity of human neuroblastoma studied in three IGR cell line models derived from bone marrow metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Expression of the multidrug resistance, MDR1, gene in neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

The prognostic value of MDR1 gene expression in primary untreated neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80

The Wnt signaling pathway and its role in tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.80